Mode
Text Size
Log in / Sign up
N/A N=21 Randomized Single-blind Treatment

Evaluation of Daytime Corneal Swelling During Wear of Galyfilcon A Lenses

Myopia

Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Apr 2015
Primary outcome: Primary: Corneal Swelling — 569.42; 574.64; 575.57; 578.99 microns

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
galyfilcon A (Device); galyfilcon A plus (Device); lotrafilcon A (Device); polymacon (Device); spectacles (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johnson & Johnson Vision Care, Inc.
Primary completion
Dec 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Corneal Swelling
569.42; 574.64; 575.57; 578.99; 573.79
PRIMARY
Limbal Redness
0.66; 0.83; 0.77; 0.91; 1.14
PRIMARY
Endothelia Blebs
4.97; 8.86; 10.93; 10.31; 8.50

Summary

The purpose of this study is to evaluate corneal swelling, limbal redness, and endothelial bleb response to wearing galyfilcon A lenses in asian eyes.

Eligibility Criteria

Inclusion Criteria

  • Be of legal age (i.e. 18 years)
  • Be of Asian descent and have -Asian eye‖ identifying features (see Appendix A)
  • Be mentally competent, willing and able to sign a written informed consent form.
  • Have contact lens distance sphere requirement in the range 1.00D to 6.00D.
  • Have spectacle astigmatism <1.25D in each eye
  • Currently wear soft contact lenses (for at least 3 months prior to the trial ) without experiencing difficulties or contact lens related complications
  • Have had an oculo-visual examination within the previous 12 months.
  • Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
  • No evidence of lid abnormality or infection
  • No conjunctival abnormality or infection
  • No clinically significant slit lamp findings (i.e. edema, staining, scarring, vascularization, infiltrates or abnormal opacities)
  • No other active ocular disease

Exclusion Criteria

  • Requires concurrent ocular medication.
  • Clinically significant (Grade 3 or 4) corneal staining (FDA scale), corneal stromal haze, corneal vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear.
  • Has had refractive surgery.
  • Has had any anterior ocular surgery. Has had any other ocular surgery or injury within 8 weeks immediately prior to enrolment for this study.
  • History of abnormal lachrymal secretions.
  • Pre-existing ocular irritation that would preclude contact lens fitting.
  • Keratoconus or other corneal irregularity.
  • Extended lens wear in last 3 months.
  • PMMA, hybrid or RGP lens wear in the previous 8 weeks
  • Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear.
  • Has diabetes
  • Known/reported infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV).
  • History of chronic eye disease (e.g. glaucoma or ARMD).
  • Pregnancy, lactating, or planning a pregnancy at the time of enrolment.
  • Participation in any concurrent clinical trial or in last 30 days.
  • Family member or employee of the clinical site, investigator or other study staff.
  • Currently wears habitual contact lenses on an EW basis.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01482819). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search